The purpose of this study is to learn whether the study vaccine and adjuvants (drugs that are used to help improve immune responses) have an acceptable safety profile in treating individuals with HIV. A second purpose of this study is to understand how the immune system responds to the study vaccine and adjuvants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
Unnamed facility
Sacramento, California, United States
Unnamed facility
Denver, Colorado, United States
Unnamed facility
Chicago, Illinois, United States
Unnamed facility
New York, New York, United States
To evaluate the safety and tolerability of the HIV CTL MEP vaccine formulated with adjuvants, administered by intramuscular (IM) injection to HIV Pos adults receiving stable HAART. Subjects will receive vaccinations at months 0, 1, 3, and 6.
To evaluate the subject immune system responds to the vaccinations. To evaluate RNA and protein patterns in the collected blood samples after vaccination.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Cleveland, Ohio, United States
Unnamed facility
Philadelphia, Pennsylvania, United States
Unnamed facility
Nashville, Tennessee, United States
Unnamed facility
Austin, Texas, United States
Unnamed facility
Dallas, Texas, United States
Unnamed facility
Dallas, Texas, United States